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Association of antidiabetic 
medication and statins 
with survival from ductal 
and lobular breast carcinoma 
in women with type 2 diabetes
Mayu Hosio1*, Elina Urpilainen2, Ari Hautakoski3, Mikko Marttila4, Martti Arffman5, 
Reijo Sund6, Anne Ahtikoski7, Ulla Puistola2, Esa Läärä3, Peeter Karihtala1,8,9 & 
Arja Jukkola10,11
We investigated the survival of female patients with pre-existing type 2 diabetes (T2D) diagnosed 
with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) of breast, in relation to the 
use of metformin, other antidiabetic medication (ADM) and statins. The study cohort consisted of 
3,165 women (2,604 with IDC and 561 with ILC). The cumulative mortality from breast cancer (BC) and 
from other causes was calculated using the Aalen-Johansen estimator. The cause-specific mortality 
rates were analysed by Cox models, and adjusted hazard ratios (HRs) were estimated for the use of 
different medications. No evidence of an association of metformin use with BC mortality was observed 
in either IDC (HR 0.92, 95% confidence interval [CI] 0.64–1.31) or ILC (HR 0.68, 95% CI 0.32–1.46) 
patients, when compared to other oral ADMs. The mortality from other causes was found to be lower 
amongst the IDC patients using metformin (HR 0.64, 95% CI 0.45–0.89), but amongst ILC patients the 
evidence was inconclusive (HR 1.22, 95% CI 0.64–2.32). Statin use was consistently associated with 
reduced mortality from BC in IDC patients (HR 0.77, 95% CI 0.62–0.96) and ILC patients (HR 0.59, 95% 
CI 0.37–0.96), and also mortality from other causes in IDC patients (HR 0.81, 95% CI 0.67–0.96) and 
in ILC patients (HR 0.66, 95% CI 0.43–1.01). We found no sufficient evidence for the possible effects of 
metformin and statins on the prognosis of BC being different in the two histological subtypes.
Breast cancer (BC) is the most common cancer and an important cause of death amongst women  globally1. Fur-
thermore, patients with type 2 diabetes (T2D), who are diagnosed with breast cancer, have a worse  prognosis2,3. 
Invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) are the two main histological subtypes 
of BC, comprising 72–80% and 5–15% of all invasive breast cancers,  respectively4,5.
Oestrogen receptor (ER) positivity is more common in ILC, whereas human epidermal growth factor recep-
tor 2 (HER2) overexpression is rare in this tumour  type6. One of the main biological differences between these 
subtypes is the loss of expression of E-cadherin, which is observed frequently in ILC  cells7. E-cadherin is a cell 
adhesion molecule expressed in normal breast tissue and is useful as a phenotypic marker in  BC8.
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ILC is more often detected in older women and is larger at diagnosis than IDC, tending to have an increased 
number of involved lymph nodes and indicating distinct metastatic behaviour than  IDCs9,10. Although results 
on the prognosis of IDC and ILC vary, many studies have reported a similar prognosis for patients with ILC 
compared with  IDC10.
Metformin is a widely prescribed oral biguanide antidiabetic medication (ADM) used as first-line therapy 
for patients with  T2D11. It enhances insulin sensitivity and decreases insulin  resistance12. Metformin use has 
been shown to reduce cardiovascular events in T2D  patients13,14. The results of previous epidemiological studies 
on the association between metformin and survival of breast cancer patients with T2D are  heterogenous15–22.
Statins i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are the most pre-
scribed medication to lower lipid level in blood. In Finland, statins are prescribed for about 80% of patients with 
diabetes for secondary prevention and by 40% for primary prevention of cardiovascular  diseases23. It has been 
reported that statins might also have a potential anticancer  role24–27. However, previous epidemiologic studies 
on statins and their association with BC prognosis are  inconclusive28–32.
Although there are noteworthy differences in the two main histological subtypes of BC, treatment guidelines 
do not give specific recommendations according to the  histology33. In this study, we investigated the survival of 
IDC and ILC patients in relation to the use of metformin, other ADM, and statins in women with T2D, since 
this question has not been addressed previously.
Materials and methods
We have followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guide-
lines for  reporting34. The Diabetes in Finland database (FinDM) was used to extract the data of women with 
T2D. The FinDM database holds information from multiple nationwide registers, including the Special Refund 
Entitlement Register and the Prescription Register from the Social Insurance Institution, the Care Register for 
Health Care and the Hospital Discharge Register from the Finnish Institute for Health and Welfare, and the 
Causes of Death Register from Statistics  Finland35.
The FinDM database includes the records of more than 240,000 women with T2D and contains reliable 
information on ADM and other types of medications reimbursed since  199435. A patient is entered into the 
database at the time of the first reimbursement for ADMs or when there is a diabetes diagnosis in some of the 
incorporated registers, which have records dating back to  196435. Data on diagnoses held in hospital records 
are available from 1969 onwards for inpatients and from 1998 onwards for  outpatients35. The classification of 
patients into type 1 and type 2 diabetes is mainly based on the ADM used as the first-line treatment. In contrast 
to a local diabetes register, the FinDM data appear to have good coverage of patients with  diabetes36. Data on 
cancer cases, including information on stage, were obtained by record linkage of the FinDM cohort with the 
Finnish Cancer Registry (FCR)37.
From the FinDM database, we identified 13,804 women with T2D who had also been diagnosed with BC. The 
additional inclusion criteria were as follows: BC diagnosed between 1998 and 2011, estimated T2D duration of at 
least 180 days before BC diagnosis, patients at least 40 years old when T2D was diagnosed, and the histological 
type of BC was ductal or lobular. Women with a prior cancer diagnosis (other than non-melanoma skin cancer) or 
whose BC were diagnosed at autopsy were excluded (Figure 1). Follow-up of the study cohort started at the date 
of diagnosis of BC and ended at the date of death, emigration or 31st of December 2013, whichever occurred first.
The patients were classified into the following mutually exclusive groups, according to their use of ADM 
within the three-year period before BC diagnosis: (1) metformin only; (2) other oral ADM only; (3) metformin 
T2D less than 180 days earlier
N=2,958









Other types than ductal or lobular
N=368
Breast cancer diagnosis before 1998 or after 2011
N=6,610
Diabetes diagnosis before the age of 40
N=150
Figure 1.  Cohort selection flowchart.
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combined with other oral ADM; (4) insulin at any time; and (5) no history of regular ADM use. Statin use was 
assessed in two groups: users and non-users. Exposure to all forms of medication within the three-year period 
before BC diagnosis was defined as starting no earlier than 180 days after the date of the first purchase. A patient 
who first purchased an oral ADM less than 180 days before the diagnosis of BC was categorised as having no 
history of regular ADM use. A single purchase of insulin within the period was enough to categorise the patient 
into the insulin group. A patient who had purchased a statin more than 180 days before the diagnosis of BC was 
categorised into the statin user group.
The FCR was used to gather the follow-up information. The dates and causes of death from the Cause of 
Death Register maintained by Statistics Finland are regularly linked with the FCR records. Assessment of each 
cancer patient’s cause of death takes into account all the data available in the FCR record, and on that basis 
the FCR personnel decide whether the patient died from that cancer or from some other cause. Accordingly, 
in this study, the causes of death were classified into two groups: death from BC and death from other causes. 
Information on emigration was also obtained from the FCR, as the data are linked with the Central Population 
Register of Finland, which holds information on individuals’ emigration and official place of residence prior to 
date of  diagnosis38.
The stage of cancer at diagnosis is categorised in FCR as follows: 0) unknown, (1) localized, (2) non-localised, 
only regional lymph node metastases, (3) metastasised or invades adjacent tissues, (4) non-localised, no informa-
tion on extent, (5) locally advanced, tumour invades adjacent tissues, and (6) non-localised, also distant lymph 
node metastases. Thus, the stage coding has been as follows in our study: (0) unknown, (1) local, (2–6) advanced.
The cumulative mortality from BC and from other causes was described by using the Aalen-Johansen estima-
tor of cumulative incidence function for competing risks in the different medication  groups39,40. To control for the 
effects of calendar year, age and stage at time of BC diagnosis, and T2D duration, the Cox proportional hazard 
models were fitted for the two causes of death separately, from which adjusted hazard ratios with 95% confidence 
interval were calculated. Potential differences in the HRs between the IDC and ILC patients were assessed by 
pertinent interaction terms in Cox models fitted for the whole cohort of BC patients. For model diagnostics, 
the plots of the scaled Schoenfeld residuals were visually  scrutinised41, but no evidence for a violation of the 
proportional hazard’s assumption could be found that would have had any essential impact on the inference. R 
environment, version 3.6.1, was utilised throughout for statistical  analyses42. The Cox models were fitted, and 
the assumptions were checked with the functions provided by the survival  package43.
Ethics declarations. All procedures performed in this study involving human participants were in accord-
ance with the ethical standards of the Finnish national research committee and the 1964 Declaration of Helsinki 
and its later amendments. According to Finnish legislation, no separate ethics approval is needed for studies 
that involve only administrative registers. However, ethics approval was obtained for the FinDM study from the 
research ethics committee of the Finnish Institute of Health and Welfare (30 January 2014, meeting 1/2014, 340 
§609). Permission to use data was obtained from those maintaining the original registers (the Finnish Institute 
for Health and Welfare, the Social Insurance Institution and Statistics Finland).
Consent to participate. According to Finnish legislation, no separate informed consent is needed for 
studies that involve only administrative registers.
Results
The final cohort included 3,165 women with BC and T2D: 2,604 with IDC and 561 with ILC (Fig. 1). The age 
range was 41–100 years at the time of BC diagnosis. Amongst the BC patients, 19% were classified as metformin 
users, 12–14% were users of other oral ADM, and 28% had no history of regular ADM use. No essential differ-
ences were found between IDC and ILC groups with regard to the use of different prediagnostic ADM (Table 1). 
In both the IDC and ILC groups, the patients in the insulin group had the longest duration of T2D and patients 
in the metformin group the shortest duration before BC diagnosis. Statins were used by 40% of the patients with 
IDC, and 36% with ILC. The most commonly used statins were lipophilic simvastatin and atorvastatin.
The unadjusted 10-year cumulative mortality of BC varied from 17% to 24% across the different ADM groups 
in the IDC patients and from 18% to 28% in the ILC patients. The unadjusted 10-year cumulative mortality of 
other causes varied from 22% to 45% across the different ADM groups in the IDC patients and from 20% to 
47% in the ILC patients. (Figure 2a).
In the Cox proportional hazards model, a more advanced BC stage and older age were associated with 
increased mortality from BC in both the IDC and the ILC patients. No sufficient evidence for systematic vari-
ability in the mortality from BC was observed in the metformin users amongst either the IDC (HR 0.92, 95% CI 
0.64–1.31) or the ILC (HR 0.68, 95% CI 0.32–1.46) patients. In the IDC patients, mortality from other causes of 
death was found to be lower amongst the metformin users (HR 0.64, 95% CI 0.45–0.89) compared to the users of 
other oral ADM. Amongst the ILC patients, the result was inconclusive: mortality from other causes appeared to 
be higher in metformin users (HR 1.22, 95% CI 0.64–2.32), but the wide confidence interval was also statistically 
compatible with the result in IDC patients. The mortality from other causes was higher in insulin users in both 
the IDC and the ILC patients compared to the users of other oral ADMs (Table 2). When analysing pertinent 
interactions of the studied medications with the histologic type in a joint Cox model covering all BC patients, 
no evidence for any HR differences between IDC and ILC could be discerned (data not shown).
Amongst the IDC patients, the 10-year cumulative BC mortality was 16% in statin users and 21% in non-
users, and amongst the ILC patients these proportions were 19% and 25%, respectively. In the IDC patients, the 
10-year cumulative mortality from other causes was 31% in statin users and 36% in non-users, and amongst ILC 
patients these proportions were 28% and 33%, respectively (Figure 2b). Prediagnostic statin use was found to be 
4
Vol:.(1234567890)
Scientific Reports |        (2021) 11:10445  | https://doi.org/10.1038/s41598-021-88488-x
www.nature.com/scientificreports/
associated with decreased mortality from BC in both the IDC (HR 0.77, 95% CI 0.62–0.96) and the ILC patients 
(HR 0.59, 95% CI 0.37–0.96). Mortality from other causes was also observed to be decreased in both the IDC 
patients (HR 0.81, 95% CI 0.67–0.96) and the ILC patients (HR 0.66, 95% CI 0.43–1.01) (Table 2).
Discussion
To the best of our knowledge, this is the first study addressing the association of ADMs or statins with survival 
from BC separately in the two main histological subtypes of BC. In the present study, no evidence for an associa-
tion of metformin use with BC mortality was observed in either the IDC or the ILC patients when metformin 
use was compared with the use of other forms of oral ADM. In the IDC patients, mortality from other causes of 
death was found to be lower amongst metformin users compared to other oral ADM users. In the ILC patients, 
the result of this comparison was inconclusive due to a wide Cl, although statistically compatible with what was 
found for IDC patients. Insulin use was not found to have an association with BC mortality in either the IDC or 
the ILC patients. Prediagnostic use of statins was observed to be associated with decreased mortality from BC 
as well as from other causes of death in both the IDC and the ILC patients.
Insulin-like growth factor 1 (IGF-1) is a growth hormone that regulates cell growth, differentiation and trans-
formation in various tissues, including breast  tissue44. Increased insulin levels may induce BC carcinogenesis 
through crosstalk between insulin and insulin and IGF receptors, which are overexpressed in BC  cells44. Of note, 
IGF-1 expression has been found to be higher in ILC than in  IDC45, and increased IGF-1 expression has been 
observed to be associated with increased BC tumour size and relapse with distant metastasis, especially in ILC, 
but the association between IGF-expression and BC survival outcomes is  variable46–48.
Preclinical studies have suggested that metformin could inhibit the growth of BC cells via indirect and direct 
pathways by reducing the level of blood glucose and insulin, which involves AMPK-dependent and -independ-
ent  mechanisms49,50. A decrease in all-cause mortality for metformin users was reported in a meta-analysis of 
survival studies of BC patients with T2D, showing an overall 45% risk reduction in the total mortality rate pooled 
from 11  studies51. Vissers et al. have reported a reduced BC mortality rate only in long-term metformin  users52.
Table 1.  Distribution of baseline characteristics and outcome status in ductal and lobular carcinoma. 
a Interquartile range. b Other oral antidiabetic medication. c Antidiabetic medication.
Ductal carcinoma (%) Lobular carcinoma (%) Total
Total n 2604 561 3165
Age at breast cancer diagnosis (years)
Median  (IQRa) 72 (64–79) 72 (64–79) 72(64–79)
40–59 392 (15) 86 (15) 478 (15)
60–69 785 (30) 169 (30) 954 (30)
70–79 825 (32) 177 (32) 1002 (32)
80–100 602 (23) 129 (23) 731 (23)
Duration of diabetes (years)
Median  (IQRa) 6.5 (3.2–10.9) 6.5 (2.9–11.3) 6.5(3.2–11.0)
0.5–3 606 (23) 142 (25) 748 (24)
3–6 612 (24) 121 (22) 733 (23)
6–12 832 (32) 183 (33) 1015 (32)
12–42 554 (21) 115 (20) 669 (21)
Prediagnostic ADM use
Metformin 483 (19) 105 (19) 588 (19)
Otherb 324 (12) 78 (14) 402 (13)
Metformin and  otherb 569 (22) 114 (20) 683 (22)
Insulin 495 (19) 105 (19) 600 (19)
No history of regular  ADMc use 733 (28) 159 (28) 892 (28)
Prediagnostic statin use
Statin 1035 (40) 202 (36) 1237 (39)
No statin 1569 (60) 359 (64) 1928 (61)
Stage
Local 1288 (49) 257 (46) 1545 (49)
Advanced 1143 (44) 259 (46) 1402 (44)
Unknown 173 (7) 45 (8) 218 (7)
Outcome at the end of follow up
Breast cancer death 431 (17) 113 (20) 544 (17)
Other death 688 (26) 138 (25) 826 (26)
Alive 1485 (57) 310 (55) 1795 (57)
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Figure 2.  (a) Cumulative mortality curves in ADM groups amongst the invasive ductal and the lobular 
carcinoma. ADM = antidiabetic medication, M&O = metformin and other oral ADM. (b) Cumulative mortality 
curves in statin groups amongst the invasive ductal and the lobular carcinoma.
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The reference group selection is an important difference between most previous studies and ours. The refer-
ence group for metformin users was non-users of metformin in various previous  studies15–18,21,22,52,53, while we 
compared metformin users to users of other oral ADMs. We assume that a reference group of ‘never used met-
formin’ might lead to overestimation of the possible positive association between metformin and BC survival, 
since this reference group also includes insulin users, whose mortality is expected to be elevated in any  case54. 
There are epidemiological data that show that BC patients with T2D treated with insulin alone or sulphony-
lurea monotherapy had increased BC  mortality3. Sulphonylureas are also widely used to treat T2D since they 
are insulin secretagogues from pancreatic β-cells55. This positive effect on insulin and IGF levels may progress 
 tumorigenesis56. In the present study, most of the users of other oral ADM were sulphonylurea users.
Statin use reduces the risk of cardiovascular disease events in patients with T2D even without a prior history of 
coronary  disease57,58. Beyond cholesterol metabolism, the mevalonate pathway is indispensable for the oncogene 
p53’s tumour-increasing  effects59. Therefore, reducing mevalonate levels with statins accelerates the apoptosis 
of cancer  cells27,60. Similar to our results, many studies have reported lower mortality from both BC and other 
causes in statin  users61–65. However, the study populations in these studies were not limited to women with T2D. 
In particular, simvastatin, a highly lipophilic statin, has been associated with a decreased risk of BC recurrence 
or prognosis, while the association between hydrophilic statin use and BC recurrence was much more  unsure63. 
Further, in a cohort study, Murtola et al. reported that simvastatin users had a decreased risk of BC mortality 
only amongst patients with metastatic BC at  diagnosis61. In in vitro studies, only lipophilic statins were observed 
to inhibit BC cell  proliferation66,67. Lipophilic statins may also penetrate the cell plasma membrane more easily 
than hydrophilic statins, which is possibly associated with the inhibition of cell  growth66.
The main strength of our study is its use of nationwide database registers that hold accurate information about 
BC types and timing of diagnoses. The data quality in Finnish registers such as the Finnish Hospital Discharge 
register is regarded as  high68. All the Nordic cancer registries have high-quality standards for the completeness 
and accuracy of the registered data, and patients’ causes of death are gathered from the national cause of death 
 registries37. Furthermore, the Finnish Cause of Death Register’s practices and procedures comply with the coding 
of causes of death for mortality  statistics69, and the FCR data enabled us to distinguish between cancer-specific 
and other causes of death. The duration of diabetes is regarded as precise, since it was based on the first recorded 
Table 2.  Estimation results from Cox proportional hazard models of mortality from the two causes of death. a 
other oral antidiabetic medication. ADM = antidiabetic medication,    95% CI    = 95% confidence interval.
Mortality from breast cancer Mortality from other causes
Ductal carcinoma Lobular carcinoma Ductal carcinoma Lobular carcinoma
Variable value Hazard ratio (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI)
Year of diagnosis
1998–2002 1 1 1 1
2003–2007 0.84 (0.67–1.07) 0.98 (0.61–1.58) 0.97 (0.81–1.16) 0.98 (0.64–1.51)
2008–2011 0.96 (0.74–1.26) 1.14 (0.64–2.02) 0.80 (0.61–1.03) 0.84 (0.49–1.46)
Age at diagnosis (years)
40–59 0.97 (0.69–1.37) 1.08 (0.56–2.10) 0.61 (0.41–0.92) 0.52 (0.20–1.32)
60–69 1 1 1 1
70–79 1.58 (1.22–2.04) 2.19 (1.29–3.73) 2.95 (2.33–3.75) 2.88 (1.66–5.02)
80–100 2.66 (2.01–3.50) 2.62 (1.47–4.67) 8.55 (6.70–10.9) 7.52 (4.31–13.1)
Duration of diabetes (years)
0.5–3 1 1 1 1
3–6 0.89 (0.66–1.19) 0.87 (0.50–1.51) 1.05 (0.82–1.36) 0.99 (0.57–1.74)
6–12 1.00 (0.75–1.31) 0.86 (0.50–1.46) 1.34 (1.05–1.70) 0.91 (0.55–1.52)
≥ 12 1.08 (0.79–1.48) 0.90 (0.46–1.75) 1.23 (0.94–1.61) 1.15 (0.65–2.03)
Stage
Local 1 1 1 1
Advanced 4.61 (3.64–5.83) 5.61 (3.41–9.22) 1.12 (0.95–1.32) 0.88 (0.61–1.28)
Unknown 2.07 (1.31–3.26) 2.91 (1.25–6.77) 1.51 (1.17–1.95) 0.86 (0.45–1.64)
Prediagnostic statin use
No 1 1 1 1
Yes 0.77 (0.62–0.96) 0.59 (0.37–0.96) 0.81 (0.67–0.96) 0.66 (0.43–1.01)
Prediagnostic ADM group
Metformin 0.92 (0.64–1.31) 0.68 (0.32–1.46) 0.64 (0.45–0.89) 1.22 (0.64–2.32)
Othera 1 1 1 1
Metformin and  othera 0.76 (0.54–1.07) 1.01 (0.54–1.91) 0.93 (0.73–1.18) 1.28 (0.72–2.28)
Insulin 1.21 (0.86–1.71) 0.96 (0.47–1.95) 1.35 (1.04–1.73) 2.11 (1.14–3.91)
No history of regular ADM use 0.87 (0.63–1.19) 1.42 (0.79–2.53) 0.75 (0.59–0.95) 0.97 (0.54–1.74)
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diabetes diagnosis in any of the incorporated registers or the first purchase of any form of ADM. In Finland, most 
forms of ADM and statins are prescribed by medical doctors and reimbursed by the Social Insurance Institution, 
and hence the data on the duration of medication use are accurate.
A major limitation of our study is that the data was available only from registers, which lack information on 
traditional prognostic factors, including hormone receptor status, lymph node status, and tumour size in different 
specific BC subtypes. Further, the FCR lacks accurate data on the treatment (surgery, radiation, chemotherapy, 
and endocrine therapy). When focusing on treatments, patients with ILC may have lower response rates to 
neoadjuvant chemotherapy and worse outcomes to endocrine therapies such as tamoxifen compared to patients 
with  IDC70,71. The sensitivity to radiotherapy is suggested to be similar for IDC and ILC  patients72.
Insulin is generally required in T2D treatment in the later stages of the disease, since insulin secretion 
decreases over time in patients with  T2D73, and insulin treatment could represent a failure of earlier treatment 
or a contraindication to other types of medication, explaining general ill  health74. Hence, different characteristics 
of particular medication users may induce unintentional confounding by indication in observational  studies75, 
although choosing users of other ADM as the reference group, as in our study, would likely reduce this bias.
Moreover, we lacked information on lifestyle factors, such as the patients’ body mass index (BMI), smoking 
status, and alcohol consumption although it is known that most T2D patients are overweight or  obese76. Some 
studies have reported that obesity might be independently associated with poorer prognosis for BC  patients77, 
and metabolic syndrome has been found to be significantly associated with an increased risk of BC  recurrence78. 
A large systematic review with meta-analysis has indicated that BC patients ceasing to smoke can lower their 
BC-specific mortality  dramatically79. Previous findings regarding the association of prediagnostic alcohol con-
sumption with breast cancer-specific mortality are  mixed80–83. Additionally, the number of ILC patients in the 
final cohort was much smaller than the number of IDC patients. In consequence, the results for the ILC group 
were statistically less precise than those pertaining to the IDC group.
Conclusion
No sufficient evidence could be found for metformin use being associated with a lower BC mortality compared 
with the use of other oral ADM in either the IDC or the ILC groups. Metformin use was observed to predict 
decreased mortality from other causes of death in the IDC group, but the evidence on this was inconclusive in 
the ILC group. Prediagnostic use of statins was found to be associated with decreased mortality from BC and 
from other causes in both subgroups. We found no sufficient evidence for the possible effects of metformin and 
statins on the prognosis of BC being different in the two major histological subtypes.
Data availability
The individual-level data that support the findings of this study are not publicly available for confidentiality 
reasons. However, aggregate data and instructions to apply for individual-level data can be requested from the 
FinDM database maintainers at the Finnish Institute for Health and Welfare.
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